CME Group (CME) CCO gains net shares from performance award

Rhea-AI Filing Summary

CME Group Inc. senior managing director and Chief Commercial Officer Julie Winkler reported compensation-related share activity. She acquired 8,256 shares of Class A common stock at $311.40 per share through the vesting of performance shares granted in 2022, based on total shareholder return versus the S&P 500 over a three-year period ending December 31, 2025. To cover tax withholding obligations from this award, she surrendered 3,658 shares back to the company, resulting in a net increase of 4,598 shares and direct ownership of 30,110 shares after the transactions.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Winkler Julie

Role Sr MD Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	8,256	$311.40	$2.57M
Tax Withholding	Common Stock Class A	3,658	$311.40	$1.14M

Holdings After Transaction: Common Stock Class A — 33,768 shares (Direct)

Footnotes (1)

1. Represents the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan. The number of shares was determined based on the company's achievement of total shareholder return relative to the S&P 500 measured over a three-year performance period from January 1, 2023 through December 31, 2025. Ms. Winkler surrendered shares to the company in order to fulfill tax withholding obligations related to the receipt of the performance share award.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winkler Julie

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr MD Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	03/15/2026		A		8,256(1)	A	$311.4	33,768	D
Common Stock Class A	03/15/2026		F		3,658(2)	D	$311.4	30,110	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan. The number of shares was determined based on the company's achievement of total shareholder return relative to the S&P 500 measured over a three-year performance period from January 1, 2023 through December 31, 2025.

2. Ms. Winkler surrendered shares to the company in order to fulfill tax withholding obligations related to the receipt of the performance share award.

Remarks:

	By: Margaret Austin Wright For: Julie Marie Winkler	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CME (CME) executive Julie Winkler report in this Form 4?

Julie Winkler reported vesting of 8,256 Class A common shares as a performance-based award and the surrender of 3,658 shares for taxes. After these compensation-related transactions, she directly owns 30,110 CME Group Class A common shares.

Is Julie Winkler’s CME (CME) Form 4 a market buy or sell?

The Form 4 reflects a performance share award and tax withholding, not an open-market buy or sell. Shares were granted as compensation, and some were surrendered back to the company to cover tax obligations on the award.

How many CME (CME) shares did Julie Winkler receive and surrender?

She received 8,256 Class A common shares from the vesting of a 2022 performance share grant and surrendered 3,658 shares to satisfy tax withholding. This left her with a net 4,598 additional shares from the award.

What performance period determined Julie Winkler’s CME (CME) share award?

The performance shares vested based on CME Group’s total shareholder return relative to the S&P 500. The measurement period ran from January 1, 2023 through December 31, 2025, as specified in the performance share grant details.

How many CME (CME) shares does Julie Winkler own after these transactions?

Following the grant and tax-withholding surrender, Julie Winkler directly owns 30,110 CME Group Class A common shares. This figure reflects her updated direct ownership after the performance shares vested and related tax obligations were settled.